New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation. Caldini A et al. Clin Chem Lab Med. 2015 Nov 18. pii: /j/cclm.ahead-of-print/cclm-2015-0689/cclm-2015-0689.xml. doi: 10.1515/cclm-2015-0689. [Epub ahead of print]. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. Bagratuni T et al. Br J…
Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Siontis B et al. Blood Cancer J. 2015 Oct 23;5:e364. doi: 10.1038/bcj.2015.87. 18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Zamagni E et al. Leukemia. 2015 Oct 22. doi: 10.1038/leu.2015.291. [Epub ahead of print]. MMSA-1 expression pattern in multiple myeloma and…
MicroRNAs in urine are not biomarkers of multiple myeloma. Sedlaříková L et al. J Negat Results Biomed. 2015 Sep 23;14(1):16. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. Besse L et al. PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly…
IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay. Djidjik R et al. Pathol Biol (Paris). 2015 Aug 17. pii: S0369-8114(15)00057-7. doi: 10.1016/j.patbio.2015.06.002. [Epub ahead of print]. Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM). Cretti F et al. Radiol Med. 2015 Aug 19. [Epub ahead of print]. Clinical…
Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ayuk F et al. Ann Hematol. 2015 Jul 24. [Epub ahead of print]. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement. Oral A et al. Clin Nucl Med. 2015 Jul 22. [Epub ahead of print]. Tumor associated macrophages (TAMs) and extraczellular…
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. Watanabe T et al. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. Chhabra S et al. J…
Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM). Zacchino M et al. Eur Radiol. 2015 May 20. [Epub ahead of print]. Global hypomethylation in myeloma is associated with poor prognosis. Sive JI et al. Br J Haematol. 2015 May 26. doi: 10.1111/bjh.13506. [Epub ahead of print]. Circulating plasma cells in newly diagnosed symptomatic multiple…
Plasma cell morphology in multiple myeloma and related disorders. Ribourtout B et al. Morphologie. 2015 Apr 18. pii: S1286-0115(15)00021-1. doi: 10.1016/j.morpho.2015.02.001. [Epub ahead of print]. Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma. Zhang HT et al. Chin Med J (Engl). 2015 20th Apr;128(8):1108-1113. doi: 10.4103/0366-6999.155112. Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of…
Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Giles SL et al. Clin Radiol. 2015 Mar 19. pii: S0009-9260(15)00074-4. doi: 10.1016/j.crad.2015.02.013. [Epub ahead of print]. The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Franssen LE et al. Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038/bmt.2015.48.…
Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma. Takasu M et al. PLoS One. 2015 Feb 23;10(2):e0116842. doi: 10.1371/journal.pone.0116842. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Vij R et al. Leuk Lymphoma. 2015 Feb 20:1-12. [Epub ahead…